Evidence map›Paper›PMID 36359733›Full record

ArticleCells2022

Adipose-Derived Stem Cells (ADSCs) Supplemented with Hepatocyte Growth Factor (HGF) Attenuate Hepatic Stellate Cell Activation and Liver Fibrosis by Inhibiting the TGF-β/Smad Signaling Pathway in Chemical-Induced Liver Fibrosis Associated with Diabetes.

Sami Gharbia, Simona-Rebeca Nazarie, Sorina Dinescu, Cornel Balta, Hildegard Herman, Victor Eduard Peteu, Mihaela Gherghiceanu, Anca Hermenean, Marieta Costache

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Antioxidant therapy against TGF-β/SMAD pathway involved in organ fibrosis.Journal of cellular and molecular medicine · 2024
    Review
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Sami GharbiaDepartment of Biochemistry and Molecular Biology, University of Bucharest, 050663 Bucharest, Romania.
Simona-Rebeca NazarieDepartment of Biochemistry and Molecular Biology, University of Bucharest, 050663 Bucharest, Romania.ORCID 0000-0002-9752-6927
Sorina DinescuDepartment of Biochemistry and Molecular Biology, University of Bucharest, 050663 Bucharest, Romania.ORCID 0000-0001-7196-1712
Cornel Balta"Aurel Ardelean" Institute of Life Sciences, "Vasile Goldis" Western University of Arad, 310025 Arad, Romania.ORCID 0000-0001-5734-0071
Hildegard Herman"Aurel Ardelean" Institute of Life Sciences, "Vasile Goldis" Western University of Arad, 310025 Arad, Romania.
Victor Eduard PeteuVictor Babes National Institute of Pathology, 050096 Bucharest, Romania.
Mihaela GherghiceanuVictor Babes National Institute of Pathology, 050096 Bucharest, Romania.
Anca Hermenean"Aurel Ardelean" Institute of Life Sciences, "Vasile Goldis" Western University of Arad, 310025 Arad, Romania.ORCID 0000-0001-8510-6653
Marieta CostacheDepartment of Biochemistry and Molecular Biology, University of Bucharest, 050663 Bucharest, Romania.ORCID 0000-0002-8103-3693
University of Bucharest · ROVasile Goldis Western University of Arad · ROCarol Davila University of Medicine and Pharmacy · ROInstitutul National Victor Babes · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis can develop on the background of hyperglycemia in diabetes mellitus. However, xenobiotic-related factors may accelerate diabetes-associated liver fibrosis. In this study, we aimed to assess the antfibrotic effect of ADSC and HGF therapy and to establish the cellular and molecular mechanisms through in vitro and in vivo experiments. In vitro, TGF-β1-activated hepatic stellate cells (HSCs) were cocultured with ADSCs or HGF, and the expression of several fibrosis markers was investigated. The antifibrotic effect of the ADSCs, HGF, and ADSCs supplemented with HGF was further assessed in vivo on diabetic mice with liver fibrosis experimentally induced. In vitro results showed the inhibition of HSC proliferation and decrease in fibrogenesis markers. Coadministration of ADSCs and HGF on diabetic mice with liver fibrosis enhanced antifibrotic effects confirmed by the downregulation of Col I, α-SMA, TGF-β1, and Smad2, while Smad7 was upregulated. Moreover, stem cell therapy supplemented with HGF considerably attenuated inflammation and microvesicular steatosis, decreased collagen deposits, and alleviated liver fibrosis. In conclusion, the HGF-based ADSC therapy might be of interest for the treatment of liver fibrosis in diabetic patients, consecutive aggression exerts by different environmental factors.

Indexed as

Diabetes Mellitus, ExperimentalHepatic Stellate CellsLiver CirrhosisAnimalsHepatocyte Growth FactorMesenchymal Stem CellsMiceSignal TransductionSmad ProteinsStem CellsTransforming Growth Factor betaTransforming Growth Factor beta1Hepatocyte Growth FactorSmad ProteinsTransforming Growth Factor betaTransforming Growth Factor beta1adipose-derived stem cellsdiabetes mellitushepatic stellate cellshepatocyte growth factorliver fibrosisTGF-β/Smad pathway

Identifiers

PMID36359733
PMCPMC9653841
OpenAlexW4307327456

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.